Lv Xiangmin, Martin Jesse, Hoover Heather, Joshi Bishnu, Wilkens Margaret, Ullisch David A, Leibold Thomas, Juchum John S, Revadkar Sanket, Kalinovska Barbara, Keith Justin, Truby Adam, Liu Gui, Sun Elaine, Haserick John, DeGnore Jon, Conolly Joseph, Hill Adrian V S, Baldoni John, Kensil Charlotte, Levey Dan, Spencer Alexandra J, Gorr Gilbert, Findeis Mark, Tanne Antoine
Agenus, Inc, Lexington MA, USA.
Phyton Biotech GmbH, Ahrensburg, Germany.
iScience. 2024 Jan 26;27(3):109006. doi: 10.1016/j.isci.2024.109006. eCollection 2024 Mar 15.
Many vaccines, including those using recombinant antigen subunits, rely on adjuvant(s) to enhance the efficacy of the host immune responses. Among the few adjuvants clinically approved, QS-21, a saponin-based immunomodulatory molecule isolated from the tree bark of (QS) is used in complex formulations in approved effective vaccines. High demand of the QS raw material as well as manufacturing scalability limitation has been barriers here. We report for the first-time successful plant cell culture production of QS-21 having structural, chemical, and biologic, properties similar to the bark extracted product. These data ensure QS-21 and related saponins are broadly available and accessible to drug developers.
许多疫苗,包括那些使用重组抗原亚基的疫苗,都依赖佐剂来增强宿主免疫反应的效力。在少数几种临床批准的佐剂中,QS-21是一种从皂树树皮中分离出的基于皂苷的免疫调节分子,它被用于已批准的有效疫苗的复合配方中。QS原材料的高需求以及生产规模的限制一直是这里的障碍。我们首次报告成功地通过植物细胞培养生产出了具有与树皮提取物相似的结构、化学和生物学特性的QS-21。这些数据确保了QS-21和相关皂苷可供药物研发人员广泛获取。